[The analysis of failures in the treatment of children with chronic myelocytic leukemia in the studies of Polish pediatric leukemia/ lymphoma group].
94 children with chronic myelocytic leukaemia--CML treated in period 1975-1998 were included in the study. Twenty seven of 60 children were treated with hydroxyurea or busulfan with 6 MP. In 33 children aged 1, 5-17 years IFN (Interferon alfa) was applied at the dose of 3 millions units every second day subcutaneously. Our data showed that IFN alfa could be applied as an alternative treatment in children with CML, who have not a donor for allogenic BMT (bone marrow transplantation).
Chybicka
A
A
Kliniki Hematologii i Chorób Rozrostowych Dzieci, Akademii Medycznej we Wrocławiu.
Bogusławska-Jaworska
J
J
Kałwak
K
K
Turkiewicz
D
D
Armata
J
J
Balcerska
A
A
Cwiklińska
M
M
Hicke-Roberts
A
A
Kaczmarek-Kanold
M
M
Kołecki
P
P
Kowalczyk
J
J
Krauze
A
A
Matysiak
M
M
Płoszyńska
A
A
Rokicka-Milewska
R
R
Sońta-Jakimczyk
D
D
Sikorska-Fic
B
B
Wiśniewska-Slusarz
H
H
Wysocki
M
M
Wachowiak
J
J
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007223:Infant; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D011044:Poland; D012189:Retrospective Studies; D015996:Survival Rate; D017211:Treatment Failure
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D002066:Busulfan; D006918:Hydroxyurea